simvastatin has been researched along with Flushing in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Curran, MP; Sanford, M | 1 |
| Brinton, EA; Jiang, P; Kashyap, ML; Padley, RJ; Thakkar, RB; Vo, AN | 1 |
| Bajorunas, DR; Davidson, MH; Karas, RH; Kashyap, ML; Keller, LH; Knopp, RH | 1 |
1 review(s) available for simvastatin and Flushing
| Article | Year |
|---|---|
Niacin extended-release/simvastatin.
Topics: Animals; Clinical Trials as Topic; Drug Combinations; Flushing; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Niacin; Simvastatin; Vitamins | 2008 |
1 trial(s) available for simvastatin and Flushing
| Article | Year |
|---|---|
Long-term safety and efficacy of a combination of niacin extended release and simvastatin in patients with dyslipidemia: the OCEANS study.
Topics: Adult; Aged; Aged, 80 and over; Cholesterol; Cholesterol, HDL; Delayed-Action Preparations; Drug Combinations; Dyslipidemias; Female; Flushing; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Longitudinal Studies; Male; Middle Aged; Niacin; Simvastatin; Triglycerides | 2008 |
1 other study(ies) available for simvastatin and Flushing
| Article | Year |
|---|---|
Niacin extended-release therapy in phase III clinical trials is associated with relatively low rates of drug discontinuation due to flushing and treatment-related adverse events: a pooled analysis.
Topics: Clinical Trials, Phase III as Topic; Delayed-Action Preparations; Dose-Response Relationship, Drug; Drug Therapy, Combination; Dyslipidemias; Female; Flushing; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Lovastatin; Male; Medication Adherence; Middle Aged; Niacin; Simvastatin | 2011 |